erlotinib hydrochloride has been researched along with Scalp Dermatoses in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Consuegra, G; Fernandez-Penas, P; Hui, R; Liu, RC; Zhao, CY | 1 |
| Cheng, PS; Lai, FJ | 1 |
2 other study(ies) available for erlotinib hydrochloride and Scalp Dermatoses
| Article | Year |
|---|---|
Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone.
Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Dapsone; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Scalp Dermatoses; Treatment Outcome | 2018 |
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses | 2013 |